Abstract
BACKGROUND: The prognosis of triple-negative breast cancer (TNBC) is dismal due to aggressive behaviors. Emergence of patient-derived tumor organoids (PDTOs) allows for biomarker identification and drug screening to identify potential drugs at the patient-specific level. Here, we described a case of metastatic TNBC who obtained partial response in the liver metastatic lesions after treatment with sacituzumab govitecan that was identified highly sensitive by the PDTOs. CASE PRESENTATION: A 50-year-old woman visited our hospital for re-examination due to over 9 years after surgery for the left breast cancer. In February 2024, she experienced liver metastasis. In combination with medical history and immunohistochemistry results, metastatic TNBC was diagnosed. Based on the PDTO drug sensitivity testing, the patient was treated with highly sensitive sacituzumab govitecan. After 6 cycles of treatment, liver metastatic lesions were reduced partially. CONCLUSION: In our case of TNBC, partial response is achieved in the liver metastatic lesions after treatment based on the PDTOs, unveiling that the PDTO, a potential companion tool for selection of treatment options, can facilitate the personalized treatment in metastatic TNBC patients to improve the prognosis.